The effects of rasagiline on sleep quality were investigated in Parkinson's disease (PD) patients with sleep disturbances. Rasagiline showed beneficial effects on sleep quality in PD patients with sleep disturbances, as measured by polysomnography. Findings revealed that neither associated with motor improvement nor translated into improved overall sleep quality perception by patients.
https://www.mdlinx.com/internal-medicine/medical-news-article/2018/01/12/rasagiline-polysomnographic-sleep-parameters-parkinson-s/7499855/?rcid=96
###
From the Original Journal of Neurology
Abstract
Objective
To study the effects of rasagiline on sleep quality in Parkinson's disease (PD) patients with sleep disturbances.
Introduction
Sleep disorders are common in PD. Rasagiline is widely used in PD patients, but double-blind polysomnographic trials on its effects on sleep disturbances are missing.
Methods
Single-center, double-blind, baseline-controlled investigator-initiated clinical trial of rasagiline 1 mg/day over 8 weeks in PD patients with sleep disturbances. Blinding was achieved by running a strategic matched-placebo parallel group. Co-primary outcome measures were the changes between baseline and end-of-treatment period of sleep maintenance/efficiency as assessed by polysomnography and of the PD Sleep Scale Version 2 (PDSS-2).
Results
Twenty out of 30 patients were randomized to rasagiline (mean±SD age: 69.9±6.9 years; 10 male; Hoehn-Yahr stage: 1.9±0.8). Compared to baseline, at the end-of-treatment period sleep maintenance was significantly increased (relative change normalized to baseline: +16.3±27.9%; p=0.024, paired two-sided t-test) and a positive trend for sleep efficiency has been detected (+12.1±28.6%, p=0.097). Treatment with rasagiline led to significantly decreased wake-time-after-sleep-onset (WASO), number of arousals, percentage of light sleep and improved daytime sleepiness measured by Epworth Sleepiness Scale. We did not observe changes in the co-primary endpoint PDSS-2, and no correlations of polysomnographic sleep parameters or PDSS-2 with motor function (Unified PD Rating Scale motor score). Rasagiline was well tolerated with no unexpected adverse events.
Conclusions
In PD patients with sleep disturbances rasagiline showed beneficial effects on sleep quality as measured by polysomnography likely neither related to motor improvement nor translating into improved overall sleep quality perception by patients.
http://onlinelibrary.wiley.com/doi/10.1111/ene.13567/abstract
No comments:
Post a Comment